During Friday’s trading session, Strides Pharma Science Limited delivered a spectacular performance. Following its Q2 FY26 results, the stock surged 15.5%, touching a 52-week high of ₹979. By market close, the stock settled at ₹934.65, still up nearly 10% for the day.
Over the past year, the stock has delivered an impressive 198% return, meaning an investment made a year ago has nearly tripled. Even in the last month alone, the stock is up about 13%.
Q2 FY26 Results
According to the latest financial results, Strides Pharma reported a net profit of ₹131.5 crore in Q2 FY26. This reflects:
- 24% QoQ growth
- 83% YoY growth
Key metrics:
| Metric | Q1 FY26 | Q2 FY26 | Growth |
|---|---|---|---|
| Revenue (₹ Cr) | 1,120 | 1,221 | +9% QoQ |
| Net Profit (₹ Cr) | 105.6 | 131.5 | +24% QoQ |
| EBITDA (₹ Cr) | 184.7 | 231.6 | +25.4% YoY |
The company’s EBITDA margin improved to 19%, up from 15.8% last year.
Gross margin also rose 500 basis points to 57.8%, reflecting better operational efficiency and cost management.
Strong Performance in US and Europe Markets
The US remains Strides Pharma’s most critical market.
In Q2, the company recorded $73 million in US sales, maintaining performance at last year’s levels.
Management has reiterated its target of achieving $400 million revenue from the US business by FY27–28.
In Europe, deal activity remained strong. With new partner additions and portfolio expansion, the company expects better growth from its UK business in the coming half-year.
Management highlighted three key growth drivers for the European segment:
- Expansion of product portfolio and customer base
- Converting a strong pipeline of new opportunities
- Maintaining steady momentum in regulatory filings
What the Company Does
Strides Pharma is a global pharmaceutical company known for IP-based niche products.
Its major markets include:
- United States
- Europe
- Australia
- South Africa
The company manufactures finished dosage forms, including tablets, capsules, softgels, injectables, and creams. It operates in both branded and generic segments.
Conclusion
Strides Pharma’s strong Q2 FY26 results show that the company is rapidly improving both profitability and global presence.
Improved margins, robust international business, and clear growth guidance have strengthened investor confidence.
1 thought on “This Pharma Stock Hits 52-Week High After Explosive Q2 Profit Growth”